Plasma YKL-40: A Potential New Cancer Biomarker?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Morrison BW , LederP: Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.Oncogene.9, 3417–3426 (1994).
Johansen JS M⊘llgårdK: YKL-40: common and distinct in cancer and autoimmunity frequent in early development and abundant in human embryonic stem cells. In: International Symposium Honoring Prof. David Naor.Jerusalem Israel 2–3 September 2007 (Abstract 18).
Krona A , AmanP, OrndalC, JosefssonA: Oncostatin M-induced genes in human astrocytomas.Int. J. Oncol.31, 1457–1463 (2007).
Lal A , LashAE, AltschulSFet al.: A public database for gene expression in human cancers.Cancer Res.59, 5403–5407 (1999).
Tanwar MK , GilbertMR, HollandEC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.Cancer Res.62, 4364–4368 (2002).
Volck B , PricePA, JohansenJSet al.: YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils.Proc. Assoc. Am. Phys.110, 351–360 (1998).
Johansen JS : Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer.Dan. Med. Bull.53, 172–209 (2006).
Junker N JohansenJS KristjansenPEG PricePA: Monoclonal antibody therapy against YKL-40 delays growth in glioblastoma xenografts. American Association for Cancer Research Annual Meeting: Proceedings (2007) (Abstract 4099).
Kavanaugh A , GenoveseM, BaughmanJet al.: Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled Phase 1 trial.J. Rheumatol.30, 449–454 (2003).
Østergaard C , JohansenJS, BenfieldT, PricePA, LundgrenJD: YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis.Clin. Diagn. Lab. Immun.9, 598–604 (2002).
Mahaney MC CzerwinskiSA RogersJ: Genetic effects on serum levels of human cartilage glycoprotein-39 (YKL-40) in a pedigreed baboon model for age-related changes and pathology in bone.Am. Soc. Bone Miner. Res. (1998) (Abstract SA121).
Matsumoto T , TsurumotoT: Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters.Clin. Exp. Rheumatol.19, 655–660 (2001).
Knudsen LS , KlarlundM, Skj⊘dtHet al.: Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.J. Rheumatol.35, 1277–1287 (2008).
Montagna GL , D’AngeloS, ValentiniG: Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.J. Rheumatol.30, 2147–2151 (2003).
Rathcke CN RaymondI KistorpC HildebrandtP FaberJ VestergaardH: Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population.Int. J. Card. (2009) (Epub ahead of print).
Lebensztejn DM , SkibaE, WerpachowskaI, Sobaniec-LotowskaME, KaczmarksiM: Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B.Adv. Med. Sci.52, 120–124 (2007).
Johansen JS , ChristensenIJ, PricePA, NielsenHJ; the Danish Colorectal Cancer Study Group: Serum YKL-40 in risk assessment for colorectal cancer. A population based, prospective study of 4987 subjects at risk of colorectal cancer.ASCO Ann. Meet. Proc.26, 212 (2008) (Abstract 4136).
Jensen BV , JohansenJS, PricePA: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.Clin. Cancer Res.9, 501–512 (2003).
Coskun U , YamacD, GulbaharO, SancakB, KaramanN, OzkanS: Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?Neoplasma54, 348–352 (2007).
Jensen BV , QvortrupC, ChristensenIJet al.: Association of biomarkers of inflammation and YKL-40 with survival of patients with metastatic colorectal cancer. Proceedings of 2008 Gastrointestinal Cancer Symposium.Orlando, FL, USA (2008) (Abstract 323).
H⊘gdall EVS , JohansenJS, KjaerSKet al.: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.Oncol. Rep.10, 1535–1538 (2003).
Thöm I , AdritzkyB, SchuchGet al.: Elevated pretreatment serum concentration of YKL-40 – an independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer.Ann. Oncol.19(Suppl. 8) (2008) (Abstract 313P).
Geertsen PF , JohansenJS, von der MaaseH, JensenBV, PricePA: High pretreatment serum level of YKL-40 is related to short survival in patients with advanced renal cell carcinoma treated with high-dose continuous intravenous infusion of interleukin-2.Ann. Meet. Proc.22, 399 (2003) (Abstract 1603).
Schultz NA BerglundÅ Johansenet al.: Plasma YKL-40 a potential new biomarker for advanced upper gastrointestinal adenocarcinomas.Presented at:2009 Gastrointestinal Cancer SymposiumCA USA 15–17 January 2009 (Abstract 176).
Johansen JS , RoslindA, PalleCet al.: Serum YKL-40 levels in patients with cervical cancer are elevated compared with patients with cervical intraepithelial neoplasia and healthy controls.ASCO Ann. Meet. Proc.24, 267 (2006) (Abstract 5047).
Krogh M BastholtL JohansenJSet al.: Predictive and prognostic value of serum YKL-40 post surgery in patients with stage IIB-III melanoma receiving adjvant interferon therapy.Presented at:Perspectives in Melanoma XII.The Hague The Netherlands 2–4 October 2008.
National Cancer for Biotechnology Information. Expressed Sequence Tags database www.ncbi.nlm.nih.gov/dbEST